Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Humana shares tumble as 2025 membership for its top-rated Medicare plans slump

Published 10/02/2024, 07:20 AM
Updated 10/02/2024, 04:56 PM
© Reuters. FILE PHOTO: U.S. flag and medicines are seen in this illustration taken, June 27, 2024. REUTERS/Dado Ruvic/Illustration/File Photo
HUM
-

By Sriparna Roy and Bhanvi Satija

(Reuters) -Humana's shares fell as much as 22.4% on Wednesday, as the health insurer said enrollments in its top-rated Medicare insurance plans dropped sharply, casting a cloud over the company's 2026 revenue and bonus payments.

The sell-off wiped nearly $4 billion from the company's market value after it said the quality rating of one of its plans, which accounts for nearly half of its Medicare Advantage (MA) memberships, fell to 3.5 down from 4.5 last year.

Based on preliminary 2025 MA star ratings data, the company estimates only a quarter of its members, or 1.6 million people, will remain enrolled in 2025 for its 4+ rating plans that cover Americans aged 65 years or older, compared with 94% in 2024.

The star ratings, given by the Centers for Medicare and Medicaid Services (CMS), can sway enrollees' choice of plan and determine government's reimbursement levels.

Humana (NYSE:HUM) believes the ratings cut was driven by a narrow miss on the higher industry thresholds, set by the CMS, on some measures.

"This represents a worst-case scenario result," said Stephens analyst Scott Fidel, who downgraded the stock to "equal weight" from "overweight".

Humana said "there may be potential errors" in the federal agency's calculation of some results, and it was exploring all options to mitigate a hit from the ratings cut to its 2026 revenue.

Oppenheimer analyst Michael Wiederhorn said the rating cut could reduce Humana's bonus payments by about $3 billion and significantly hurt enrollments and margins in 2026.

Like other health insurers, Humana has been battling with elevated costs due to higher demand for medical care, and lower-than-expected payments from the government for managing healthcare for these members.

Humana said while the 2025 rating will not impact earnings in 2024 or 2025, there was a significant risk to its ability to achieve a previously set target of "at least 3 percent" MA margins by 2027.

© Reuters. FILE PHOTO: A screen displays the logo and trading information for Humana on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., December 6, 2023.  REUTERS/Brendan McDermid/File Photo

Shares of the company, which have fallen 46.2% so far this year, closed nearly 12% lower at $246.49 after hitting a four-year low of $213.31 on Wednesday.

Star rating details for 2025 are expected to be released by the agency on or around Oct. 10.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.